Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494818 | 0.72 | MAPK8 (0.34) | MAPK8MAPK9MAPK10KDM4EALDH1A1 | |
| SCHEMBL4914776 | 0.71 | LMNA (0.37) | KDM4EALDH1A1MEN1LMNATP53 | |
| SCHEMBL5518505 | 0.71 | RAB9A (0.32) | KDM4EALDH1A1MEN1LMNATP53 | |
| SCHEMBL5493140 | 0.68 | — | — | |
| SCHEMBL5490350 | 0.64 | — | — | |
| SCHEMBL5491310 | 0.62 | ALDH1A1 (0.30) | ALDH1A1LMNA | |
| SCHEMBL4910673 | 0.60 | MEN1 (0.38) | MEN1MAPTKMT2A | |
| SCHEMBL13006863 | 0.60 | MAPK8 (0.40) | MAPK8MAPK9MAPK10KDM4EALDH1A1 | |
| SCHEMBL27553500 | 0.57 | ALDH1A1 (0.33) | ALDH1A1LMNAPKM | |
| SCHEMBL5493375 | 0.57 | MEN1 (0.33) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288123-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-30 | — | — | US | claimed |
| US-20060042024-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | NOXELL CORPORATION | 2006-03-02 | — | — | US | claimed |
| US-7288123-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1781237-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006026432-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060042024-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | NOXELL CORPORATION | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060042024-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, NOX5, JUP | MAPK8 1594/4885MAPK9 1521/4885MAPK10 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.